Page last updated: 2024-09-03

muramylnac-ala-isogln-lys-tripeptide and Fibrosarcoma

muramylnac-ala-isogln-lys-tripeptide has been researched along with Fibrosarcoma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19902 (66.67)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kurzman, ID; MacEwen, EG; Shi, F1
Jarowenko, DG; Pellis, NR; Sigler, SC1
Collins, M; Herberman, RB; Phillips, H; Schneider, M; Talmadge, JE; Wiltrout, RH1

Other Studies

3 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and Fibrosarcoma

ArticleYear
In vitro and in vivo effect of doxorubicin combined with liposome-encapsulated muramyl tripeptide on canine monocyte activation.
    Cancer research, 1993, Sep-01, Volume: 53, Issue:17

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Antibodies, Monoclonal; Dogs; Doxorubicin; Drug Carriers; Fibrosarcoma; In Vitro Techniques; Leukocyte Count; Lipopolysaccharides; Liposomes; Monocytes; Time Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha

1993
Muramyl tripeptide: an effective immunotherapy in the surgical setting for pediatric abdominal neoplasms.
    Journal of pediatric surgery, 1987, Volume: 22, Issue:6

    Topics: Abdominal Neoplasms; Acetylmuramyl-Alanyl-Isoglutamine; Animals; Female; Fibrosarcoma; Immunity, Cellular; Immunotherapy; Liposomes; Macrophage Activation; Mice; Mice, Inbred C3H; Micelles; Neoplasm Seeding; Peritoneal Neoplasms; Sarcoma, Experimental; Time Factors

1987
Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.
    Journal of immunology (Baltimore, Md. : 1950), 1985, Volume: 135, Issue:2

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Cytotoxicity, Immunologic; Fibrosarcoma; Killer Cells, Natural; Liposomes; Liver; Lung; Lung Neoplasms; Lymphoma; Male; Mice; Mice, Inbred C3H; Phosphatidylethanolamines; Spleen

1985